Image pharmaphorum Editor Views & Analysis Coronavirus pharma news roundup – 24/07/20 With coronavirus vaccine trials finally showing positive results, analysts are starting to wonder what access challenges might lie ahead. Views & Analysis MSD’s David Peacock on moving UK healthcare forward David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations. Views & Analysis The enduring innovation and behaviour changes from COVID-19 The COVID-19 crisis has accelerated the shift to a more resilient, agile and innovative digitally-enabled world within healthcare and pharma. Views & Analysis Coronavirus pharma news roundup - 17/07/20 Coronavirus vaccine trials continue – but experts warn that it’s too early to get hopes up. Meanwhile, the rise in digital health looks like it’s here to stay after the pandemic. Load more results
Views & Analysis Coronavirus pharma news roundup – 24/07/20 With coronavirus vaccine trials finally showing positive results, analysts are starting to wonder what access challenges might lie ahead.
Views & Analysis MSD’s David Peacock on moving UK healthcare forward David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations.
Views & Analysis The enduring innovation and behaviour changes from COVID-19 The COVID-19 crisis has accelerated the shift to a more resilient, agile and innovative digitally-enabled world within healthcare and pharma.
Views & Analysis Coronavirus pharma news roundup - 17/07/20 Coronavirus vaccine trials continue – but experts warn that it’s too early to get hopes up. Meanwhile, the rise in digital health looks like it’s here to stay after the pandemic.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
